Radiology company Integral Diagnostics
(ASX:IDX) has reported a 5.8 per cent increase in operating revenue to $92.8 million in the first half of the 2018 financial year, compared to the same time last year.
Underlying EBITDA is up 12.4 per cent to $19 million, compared to $17 million in the first half of 2017.
Underlying NPAT increased 23 per cent to $9 million compared to $7.5 million previously, and expects to achieve its full year normalised NPAT growth of around 20 per cent.
Free cash flow has increased 70 per cent to almost $18 million compared to $10 million, with a 93 per cent conversion compared to 62 per cent previously.
The company’s net debt has reduced by 16 per cent to $42.3 million by the end of the 2017 year, compared to $50.6 million a year ago.
A dividend of 4 cents a share is expected to be paid out in March 2018.
Shares in Integral Diagnostics
(ASX:IDX) are trading 0.88 per cent higher at $2.30.
